In biotech dealmaking, the biggest number is rarely the most important one. Biotech deal structure often matters more than headline value when determining how much economic value a company can actually realise.

A licensing agreement announced at $3 billion may generate less immediate economic value for the originating company than a smaller deal with a substantial upfront payment, clearly defined milestones and meaningful rights retained. Yet headlines tend to reward the larger number, investors often focus on the announced total, and companies may find themselves negotiating against a valuation that exists more in presentation slides than in cash flow.

This creates a persistent problem in biotechnology transactions: headline deal value is frequently mistaken for realised economic value.

As cross-border licensing between Chinese biotech companies and global pharmaceutical groups continues to evolve, understanding the structure behind the headline is becoming increasingly important. The central question is no longer simply how much a deal is worth. It is how much value each party can realistically capture, under what conditions, and over what period.

The Difference Between Deal Value and Economic Value

A typical biotech licensing agreement may combine several components: an upfront payment, development and regulatory milestones, commercial milestones, and royalties on future sales. Some transactions also include equity investments, research funding, option fees or other contingent payments.

These components are not economically equivalent.

An upfront payment provides capital at signing. A development milestone depends on reaching a specified clinical or regulatory event. A commercial milestone may require the product to achieve a particular sales threshold. Royalties depend on future commercial performance and the contractual terms governing net sales.

Consequently, two transactions with the same announced total can represent very different economic propositions.

Consider two illustrative licensing offers for the same early-stage asset:

Offer A looks more attractive in a press release. Offer B provides substantially more cash at signing.

That does not automatically make Offer B the better transaction. Offer A might offer superior royalties, a stronger development commitment or more valuable rights retention. But the comparison illustrates why headline value alone is an inadequate basis for decision-making.

The correct analysis must consider the probability of milestone achievement, the time required to receive payments, the costs of achieving them, the rights surrendered and the value retained by the original developer.

A billion-dollar agreement is not a billion dollars in the bank.

Why Milestones Have Become a Central Negotiating Tool

Milestones serve a legitimate commercial purpose. They allow a licensee to pay for future value as scientific, regulatory and commercial uncertainty declines, rather than committing the full potential consideration at the outset.

For early-stage assets, this can make transactions possible that might otherwise fail because the parties disagree about valuation.

The licensor believes its technology has substantial potential. The licensee recognises the opportunity but remains uncertain about clinical success, regulatory approval, market adoption or competitive positioning. Milestones bridge the gap by linking payments to future evidence.

However, milestones also determine how risk is distributed.

When more consideration is deferred, the licensor bears a greater share of the uncertainty surrounding future payments. The headline value may remain unchanged, but the economic exposure shifts.

This distinction matters particularly for smaller biotech companies. An agreement with a large potential value but limited upfront cash may validate a technology without providing enough capital to sustain the company’s operations, finance retained programs or fund its next stage of development.

The structure must therefore reflect not only the asset’s theoretical value, but also the licensor’s financing needs and capacity to wait.

The China Licensing Market: More Value, More Structural Complexity

China-origin biotech assets have become an increasingly important part of global pharmaceutical partnering. But the significance of this development extends beyond the number or size of transactions.

The structure of these agreements is also evolving.

According to Vision Life Sciences’ 2026 China Biotech Outbound Licensing Tracker, many transactions combine relatively limited upfront consideration with substantial contingent payments. The tracker also identifies portfolio licences, option arrangements, equity components and NewCo structures among the models used in cross-border deals.

Consider the June 2026 collaboration between Haisco and Eli Lilly. As reported by Reuters, the agreement covered innovative drug projects, with selected assets potentially eligible for licensing. Haisco disclosed the possibility of up to $87 million in upfront and near-term payments, alongside as much as approximately $3 billion in additional payments tied to future milestones.

The headline figure communicates the scale of the opportunity. The payment structure communicates how that opportunity is distributed between present consideration and future performance.

For Chinese licensors, this distinction has practical implications. A transaction may provide international validation and access to global development capabilities, while leaving the originating company dependent on future milestones for much of the potential financial return.

That may be an appropriate trade-off. It should, however, be a deliberate one.

Four Questions That Matter More Than the Headline

Before evaluating a proposed licensing or strategic transaction, companies should look beyond the announced total and examine four dimensions.

1. How much value is certain at signing?

The upfront payment should be assessed against the company’s immediate financing requirements, the value of the rights being transferred and the alternatives available.

A larger upfront can reduce financing pressure and provide greater strategic flexibility. But it should not be pursued in isolation from royalties, retained rights or other economically significant terms.

2. How achievable are the milestones?

Milestones should be evaluated against the actual development pathway, not simply the size of the payment attached to them.

Clinical milestones depend on trial design, recruitment, data quality and regulatory decisions. Commercial milestones depend on launch timing, market access, competition and sales performance.

A milestone that looks attractive on paper may have limited practical value if the triggering conditions are remote, ambiguous or substantially outside the licensor’s control.

3. Who controls the path to payment?

This is one of the most consequential questions in a licensing agreement.

If the licensee controls development priorities, trial initiation, regulatory submissions and commercial investment, its decisions may determine whether the licensor receives future payments.

The contract should therefore address development obligations, reporting, consultation rights, diligence standards and remedies if a program is delayed or deprioritised.

For multi-asset agreements, the parties should also consider what happens when one program progresses while another is discontinued.

4. What value does the seller retain?

A transaction does not have to transfer every right to monetise an asset.

Depending on the program and the parties’ capabilities, the licensor may retain territorial rights, rights to other indications, royalties, equity in a NewCo or participation in future development and commercialisation.

These retained interests can preserve upside, but they also create obligations, execution risks and potential conflicts. Their value should be assessed realistically rather than treated as free additional consideration.

NewCo and Option Structures: Alternative Routes to Value

Traditional licensing is not the only way to resolve a valuation gap.

In a NewCo structure, an asset or a group of rights is licensed to a newly established company, often backed by specialist investors. The original developer may receive cash, equity or a combination of both, while the NewCo raises capital to advance the program.

This approach can separate the financing needs of an individual asset from those of the originating company. It can also bring in investors with a focused mandate and create a distinct vehicle for subsequent partnering or exit.

Option structures provide another alternative. Rather than committing immediately to a full licence, a potential partner pays for the right to obtain specified rights after a defined period or upon the availability of additional data.

For the licensee, an option can limit early exposure while preserving access to a promising opportunity. For the licensor, it can generate near-term consideration without immediately transferring all the relevant rights.

Neither structure is inherently superior to a conventional licence. Their attractiveness depends on the asset’s maturity, the company’s financing position, the availability of alternative partners and the degree of control retained by each party.

The key is to select a structure that matches the underlying uncertainty rather than forcing every opportunity into the same contractual template.

Deal Structure Is Also a Strategic Decision

The negotiation should begin before the term sheet arrives.

A company seeking to maximise upfront cash will approach a transaction differently from one seeking a global development partner, a route into overseas markets or long-term participation in commercial success.

Likewise, a shareholder considering an outright sale may prefer immediate value realisation, while a founder-led company may be willing to accept more contingent consideration in exchange for retaining equity and future upside.

These priorities affect not only the price but also the choice of counterparty, the rights offered, the transaction timetable and the acceptable level of execution risk.

For cross-border transactions, the analysis must also account for territorial definitions, intellectual property ownership, data access, regulatory responsibilities and the allocation of development and commercial obligations. A seemingly attractive financial offer may become less compelling when these provisions are examined in detail.

This is why transaction strategy and deal structure cannot be treated as separate exercises. The structure determines how the agreed value is delivered, who bears the risk and what strategic options remain after signing.

From Headline Value to Bankable Value

In a market where large licensing figures attract attention, companies can easily become anchored to headline comparisons. But the most relevant benchmark is not necessarily the largest deal announced in the same therapeutic area.

It is the transaction that best balances immediate financing, probability-adjusted future returns, retained rights, execution risk and strategic flexibility for the specific asset and company.

For biotech founders, this means preparing a clear view of the company’s capital requirements and negotiating priorities before entering discussions. For investors, it means distinguishing contractual potential from cash that is received or reasonably expected to be received. For strategic buyers, it means designing consideration that rewards genuine value creation without transferring excessive risk at signing.

The strongest transaction is not always the one with the largest announced value. It is the one in which the economics, incentives and responsibilities are aligned well enough for both parties to create and capture value.

In biotech dealmaking, the headline tells you what a transaction might be worth. The structure tells you who gets paid, when they get paid, and what must happen first.